Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    vulvar cancer AND new jersey
Show Display Options
Rank Status Study
1 Withdrawn Chemoprevention of Cancer in the Lower Female Genital Tract: The Antineoplastic Activity of the Fungicide Ciclopirox.
Condition: Vulvar Cancer
Intervention: Drug: Ciclopirox
2 Completed Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
Condition: Vulvar Cancer
Interventions: Drug: cisplatin;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: radiation therapy
3 Completed Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva
Conditions: Lymphedema;   Perioperative/Postoperative Complications;   Vulvar Cancer
Interventions: Drug: fibrin sealant;   Procedure: surgical wound closure
4 Completed Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva
Condition: Vulvar Cancer
Intervention: Procedure: Sentinel lymph node mapping
5 Active, not recruiting Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection
Conditions: Long-Term Effects Secondary to Cancer Therapy in Adults;   Stage I Vulvar Cancer;   Stage II Vulvar Cancer;   Stage III Vulvar Cancer;   Vulvar Squamous Cell Carcinoma
Intervention: Other: Clinical Observation
6 Suspended Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Vulva
Conditions: Stage IIIA Vulvar Cancer;   Stage IIIB Vulvar Cancer;   Stage IIIC Vulvar Cancer;   Stage IVA Vulvar Cancer;   Vulvar Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
7 Completed Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Borderline Ovarian Clear Cell Tumor;   Borderline Ovarian Serous Tumor;   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Childhood Embryonal Rhabdomyosarcoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Endometrioid Stromal Sarcoma;   Gestational Trophoblastic Tumor;   Malignant Mesothelioma;   Malignant Ovarian Epithelial Tumor;   Melanoma;   Neoplasm of Uncertain Malignant Potential;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Paget Disease of the Vulva;   Recurrent Cervical Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Stage I Ovarian Cancer;   Stage I Uterine Corpus Cancer;   Stage I Vaginal Cancer;   Stage I Vulvar Cancer;   Stage IA Cervical Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Cervical Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Ovarian Cancer;   Stage II Uterine Corpus Cancer;   Stage II Vaginal Cancer;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIB Cervical Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor;   Stage III Cervical Cancer;   Stage III Uterine Corpus Cancer;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IV Uterine Corpus Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Uterine Corpus Cancer;   Uterine Corpus Leiomyosarcoma;   Vulvar Squamous Cell Carcinoma
Intervention: Other: Laboratory Biomarker Analysis
8 Terminated ChemoFx® PRO - A Post-Market Data Collection Study
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Uterine Neoplasms;   Endometrial Cancer;   Vaginal Cancer;   Vulvar Cancer;   Cervical Cancer
Intervention:
9 Completed Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
Conditions: Anal Cancer;   Cervical Cancer;   Esophageal Cancer;   Head and Neck Cancer;   Penile Cancer;   Vulvar Cancer
Interventions: Biological: human papillomavirus 16 E7 peptide;   Biological: synthetic human papillomavirus 16 E6 peptide
10 Recruiting Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
11 Not yet recruiting Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Conditions: Adenoid Cystic Carcinoma;   Adnexal Carcinoma;   Apocrine Carcinoma;   Eccrine Porocarcinoma;   Extraocular Cutaneous Sebaceous Carcinoma;   Hidradenocarcinoma;   Keratoacanthoma;   Malignant Sweat Gland Neoplasm;   Merkel Cell Carcinoma;   Microcystic Adnexal Carcinoma;   NK-Cell Lymphoma, Unclassifiable;   Non-Melanomatous Lesion;   Paget Disease;   Papillary Adenocarcinoma;   Primary Cutaneous Mucinous Carcinoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory T-Cell Non-Hodgkin Lymphoma;   Sezary Syndrome;   Signet Ring Cell Carcinoma;   Skin Basal Cell Carcinoma;   Skin Basosquamous Cell Carcinoma;   Skin Squamous Cell Carcinoma;   Spiradenocarcinoma;   Squamous Cell Carcinoma of Unknown Primary Origin;   Stage III Skin Cancer;   Stage IV Skin Cancer;   Sweat Gland Carcinoma;   Trichilemmocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Talimogene Laherparepvec

Study has passed its completion date and status has not been verified in more than two years.